Broad Anti-coronavirus Activity of Food and Drug Administration-Approved Drugs against SARS-CoV-2 <i>In Vitro</i> and SARS-CoV <i>In Vivo</i>
Stuart Weston(University of Maryland, Baltimore), Matthew B. Frieman(University of Maryland, Baltimore), James Logue(National Institutes of Health), Robert Haupt(University of Maryland, Baltimore), Krystal Matthews(University of Maryland, Baltimore), Christopher M. Coleman(University of Virginia), Hanako M. Reyes(University of Pennsylvania), Yize Li(Northeast Agricultural University), Susan R. Weiss(Philadelphia University)
Cited by 238
Related Papers
Animal models for COVID-19
|Nature|2020|877
The origins of SARS-CoV-2: A critical review
|Cell|2021|511
A human-airway-on-a-chip for the rapid identification of candidate antiviral therapeutics and prophylactics
|Nature Biomedical Engineering|2021|433
Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail
|Nature Microbiology|2021|331
Activation of RNase L is dependent on OAS3 expression during infection with diverse human viruses
|Proceedings of the National Academy of Sciences|2016|308